Drug General Information
Drug ID
D08FDX
Former ID
DNCL002525
Drug Name
MGCD265
Drug Type
Small molecular drug
Indication Non-small cell lung cancer [ICD10:C33-C34] Phase 2 [525313]
Company
MethylGene
Structure
Download
2D MOL

3D MOL

Formula
C26H20FN5O2S2
Canonical SMILES
CN1C=C(N=C1)C2=CC3=NC=CC(=C3S2)OC4=C(C=C(C=C4)NC(=S)NC(<br />=O)CC5=CC=CC=C5)F
InChI
1S/C26H20FN5O2S2/c1-32-14-20(29-15-32)23-13-19-25(36-23)22(9-10-28-19)34-21-8-7-17(12-18(21)27)30-26(35)31-24(33)11-16-5-3-2-4-6-16/h2-10,12-15H,11H2,1H3,(H2,30,31,33,35)
InChIKey
UFICVEHDQUKCEA-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Tyrosine-protein kinase receptor UFO Target Info Modulator
NetPath Pathway FSH Signaling Pathway
Pathway Interaction Database Validated transcriptional targets of deltaNp63 isoforms
Reactome VEGFA-VEGFR2 Pathway
WikiPathways miR-targeted genes in squamous cell - TarBase
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
References
Ref 525313ClinicalTrials.gov (NCT02544633) Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.